Crossmark

Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30

Crossref DOI link: https://doi.org/10.1007/s00259-017-3816-z

Published Online: 2017-09-01

Published Print: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Marinova, Milka

Mücke, Martin

Mahlberg, Lukas

Essler, Markus

Cuhls, Henning

Radbruch, Lukas

Conrad, Rupert

Ahmadzadehfar, Hojjat
License Information

Text and Data Mining valid from 2017-09-01
More Information

Article History

Received: 20 February 2017

Accepted: 22 August 2017

First Online: 1 September 2017

Compliance with ethical standards

:

: The authors declare that they have no financial or non-financial competing interests.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.This article does not contain any studies with animals performed by any of the authors.

: Informed consent was obtained from all individual participants included in the study.